Drugs / JNJ-809
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02906605 | Oct 2016 → Sep 2018 | castration-resistant prostate carcinoma | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-809 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02906605 ↗ |